Thermo Fisher Scientific Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Thermo Fisher Scientific Inc (TMO). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| Laboratory Products and Biopharma Services | – | $23.00B 53.6% | $23.82B 53.5% · +3.5% |
| Life Sciences Solutions | $8.55B 19.9% | $8.16B 19.0% · -4.5% | $8.78B 19.7% · +7.6% |
| Analytical Instruments | $7.10B 16.6% | $7.27B 16.9% · +2.3% | $7.35B 16.5% · +1.2% |
| Specialty Diagnostics | $4.32B 10.1% | $4.45B 10.4% · +2.9% | $4.60B 10.3% · +3.5% |
| Laboratory Products and Biopharma Services | $22.89B 53.4% | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.